AQA
ANIK icon

Alpha Quant Advisors’s Anika Therapeutics ANIK Stock Holding History

Alpha Quant Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$13K Hold
427
– – 0.01% 234
2018
Q4 		$14K Buy
+427
New +$15.4K 0.01% 204

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Alpha Quant Advisors's ANIK Position: Q1 2019 in Review

Alpha Quant Advisors held its Anika Therapeutics (ANIK) position steady in Q1 2019 at 427 shares worth $13K. The position accounts for 0.01% of the portfolio, ranked #234.

Alpha Quant Advisors first reported a position in ANIK in Q4 2018 and has held it in 2 quarters since. The position peaked at $14K in Q4 2018. 157 funds tracked by Wall St. Rank hold ANIK as of Q1 2019.

  • Alpha Quant Advisors held 427 shares of Anika Therapeutics worth $13K as of Q1 2019.
  • Alpha Quant Advisors left its Anika Therapeutics share count unchanged in Q1 2019.
  • Anika Therapeutics made up 0.01% of Alpha Quant Advisors's portfolio in Q1 2019, its #234 holding.
  • Alpha Quant Advisors first reported a position in Anika Therapeutics in Q4 2018 and has held it in 2 quarters since.
  • Alpha Quant Advisors's Anika Therapeutics position peaked at $14K in Q4 2018.
  • 157 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2019.

Based on Alpha Quant Advisors's 13F filing for Q1 2019, filed 8 May 2019.